Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Validates P2Y12 inhibition in practice; leaves open refinement of agents for specific high-risk subgroups.
Platelet activation occurs in response to vessel injury and is important for the arrest of bleeding. Platelet activation during disease states leads to vascular occlusion and ischemic damage. The P2Y(12) receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y(12) receptor antagonists that have proven therapeutic value.
No takes yet. Share an insight, caveat, or question.
Dorsam et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: